American scientists have identified a new and promising strategy for combating Alzheimer’s disease that may open fresh horizons in the treatment of this complex neurodegenerative disorder. The study demonstrates that enhancing a specific protein can reactivate supportive brain cells and significantly improve the clearance of harmful substances from the brain.
According to Public Relations and International Affairs, researchers at Baylor College of Medicine in the United States, using mouse models engineered to develop Alzheimer’s disease–like pathology, found that increased levels of a protein known as Sox9 markedly improve the function of brain support cells called astrocytes. Astrocytes play a critical role in maintaining brain homeostasis, and in this study they were shown to clear amyloid-beta plaques—a pathological hallmark strongly associated with Alzheimer’s disease—more efficiently.
The findings revealed that treated mice exhibited significantly better performance in behavioral and memory tests, suggesting that this intervention may help protect the brain and potentially reverse aspects of cognitive decline, a process that typically occurs in Alzheimer’s disease as a result of neuronal damage and loss.
Further mechanistic analyses indicated that the beneficial effects of Sox9 are mediated through increased expression of a receptor known as MEGF10, which is selectively expressed on the membrane of astrocytes and is directly involved in the removal of amyloid-beta plaques.
Dr. Dong-Joo Choi, a neuroscientist formerly at Baylor College of Medicine and currently at the University of Texas Health Science Center in Houston, explained that astrocytes perform a wide range of essential functions, including facilitating neuronal communication and supporting memory formation, both of which are critical for normal brain function. He noted that aging leads to profound functional changes in astrocytes, yet the contribution of these changes to brain aging and neurodegeneration has remained poorly understood.
The researchers observed that elevating Sox9 levels appears to “rejuvenate” aged astrocytes. Interestingly, previous studies have shown that Sox9 is already upregulated in the brains of individuals with Alzheimer’s disease, which may reflect an intrinsic attempt by the brain to enhance the clearance of toxic waste products.
In a complementary experiment, the team genetically engineered mice to eliminate Sox9 expression. In these animals, astrocytes displayed signs of impaired health, memory recall deteriorated, and amyloid-beta accumulation was significantly increased, further underscoring the critical role of this protein.
Dr. Choi emphasized that a key strength of the study lies in its experimental design, as the researchers worked with Alzheimer’s disease mouse models that already exhibited cognitive impairment and established amyloid plaque pathology. He noted that such models more closely resemble the clinical condition observed in many patients, compared with models in which interventions are applied before plaque formation begins.
Scientists worldwide are currently investigating Alzheimer’s disease from multiple perspectives, including therapies aimed at directly targeting amyloid-beta plaques. However, not all of these approaches have proven effective, highlighting the complexity of the disease. While there are various strategies to remove amyloid-beta aggregates or prevent their formation, it remains unclear whether these protein accumulations are a primary cause of Alzheimer’s disease or a downstream consequence of the pathological process.
Nevertheless, each new study brings researchers closer to understanding how Alzheimer’s disease progresses and how it might ultimately be halted. Although the present findings are based on animal models rather than human subjects, they provide compelling evidence that a novel and potentially significant therapeutic pathway may have been identified.
Dr. Benjamin Deneen, a neuroscientist involved in the study, noted that most current therapies focus primarily on neurons or attempt to prevent amyloid plaque formation. He emphasized that this research highlights the importance of enhancing the innate clearance capacity of astrocytes as an equally critical and previously underappreciated therapeutic strategy.
This study was published in the journal Nature Neuroscience.
